FUJIKAKE Yoshio / Professor
The Center for Clinical Pharmacology and Pharmaceutics
Department of Pharmaceutical Sciences
1. Survey on the use of thalidomide in the treatment of multiple myeloma.
2. Relationship between the number of blood culture submission and AUD.
3. Evaluation of SGLT2 inhibitors in patients with impaired renal function.
Research in our group is focused on investigation of the usefulness of thalidomide for multiple myeloma resistant to recurrence / treatment based on thalidomide proper use guidelines in 12 subjects surveyed, it was administered 100 to 200 mg / day. Regarding the effectiveness, although the presence of serum M protein was observed at 100 mg / day, there were 6 stable cases, 4 cases requiring more than 2 years from the start of administration until 200 mg / day PR was reached, increasing from 100 to 200 mg reduction of serum M protein was observed in one case.